Global Gastric Motility Disorder Drug Market Size By Type (Velusetrag, Ipamorelin), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Gastric Motility Disorder Drug Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 5.4 billion by 2031, expanding at a CAGR of 7.3% during the forecast period (2023–2031). Gastric motility disorders, including gastroparesis, chronic constipation, and functional dyspepsia, have seen a rising prevalence due to aging populations, sedentary lifestyles, and increasing incidences of diabetes. This growth is further supported by continuous research and development (R&D) efforts in gastrointestinal drug formulations and the growing awareness of gastrointestinal health.

Drivers:

1. Rising Prevalence of Gastrointestinal Disorders:

An increase in gastric motility disorders, particularly gastroparesis in diabetic patients and idiopathic cases, is significantly boosting the demand for effective treatment options.

2. Aging Population:

The global rise in the elderly population has led to increased gastrointestinal complications due to decreased gut motility and higher susceptibility to disorders, driving the demand for gastric motility drugs.

3. Advances in Drug Formulations and Delivery Systems:

Innovations in drug delivery technologies and new chemical entity (NCE) development are leading to more effective treatment options, improving patient compliance and treatment outcomes.

Restraints:

1. Side Effects and Limited Efficacy of Current Drugs:

Commonly used drugs, such as metoclopramide and domperidone, often come with adverse side effects or limited long-term efficacy, which may hinder market growth.

2. Stringent Regulatory Approvals:

Strict regulatory requirements and long timelines for clinical trials are major barriers in launching new drugs for gastric motility disorders.

Opportunity:

1. Development of Novel Therapies:

Ongoing R&D in prokinetic agents and the exploration of gut-brain axis modulators provide substantial opportunities for pharmaceutical companies to introduce next-generation therapies.

2. Expansion in Emerging Markets:

Rising healthcare access, improved diagnostic rates, and growing awareness in Asia-Pacific and Latin America offer untapped potential for market expansion.

Market by System Type Insights:

Based on system type, prokinetic agents dominate the global gastric motility disorder drug market, holding the largest market share in 2023. These drugs enhance gastric emptying and are the first-line treatment for disorders like gastroparesis. The segment is expected to maintain its lead, supported by the growing number of approved and pipeline products. Serotonin receptor modulators are anticipated to show the fastest growth due to their targeted action and emerging evidence of improved safety profiles.

Market by End-use Insights:

By end use, the hospital pharmacies segment accounted for the highest revenue share in 2023. Hospitals remain the primary point of care for patients with severe or undiagnosed motility disorders. However, online pharmacies are gaining traction, especially for chronic treatment cases, owing to convenience and increasing digital adoption in healthcare.

Market by Regional Insights:

North America led the market in 2023, attributed to advanced healthcare infrastructure, higher diagnostic rates, and the presence of key pharmaceutical players. Asia-Pacific is expected to exhibit the highest CAGR during the forecast period due to rising awareness, increasing diabetic population, and improving access to gastrointestinal healthcare solutions in countries like China and India.

Competitive Scenario:

Leading players in the global gastric motility disorder drug market include Takeda Pharmaceutical Company Limited, Pfizer Inc., AbbVie Inc., Ipsen S.A., Salix Pharmaceuticals, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. These companies are actively investing in clinical trials, expanding their regional presence, and entering strategic collaborations to strengthen their portfolios.

Scope of Work – Global Gastric Motility Disorder Drug Market

Report Metric Details

Market Size (2023) USD 3.1 Billion

Projected Market Size (2031) USD 5.4 Billion

CAGR (2023–2031) 7.3%

Market Segments System Type (Prokinetic Agents, Serotonin Receptor Modulators, Others), End-Use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region

Growth Drivers Rising prevalence of gastrointestinal disorders, aging population, advancements in drug development

Opportunities Development of novel therapies, expanding access in emerging markets

Key Market Developments:

2023: Takeda launched a Phase III trial for its next-generation serotonin receptor agonist for treating chronic idiopathic constipation.

2024: Pfizer expanded its GI drug portfolio by acquiring a biotech startup specializing in gut motility regulation.

2025: AbbVie partnered with a digital health company to integrate symptom monitoring for gastric motility disorders via mobile apps, improving treatment adherence.

FAQs:

1) What is the current market size of the Global Gastric Motility Disorder Drug Market?

The market was valued at USD 3.1 billion in 2023.

2) What is the major growth driver of the Global Gastric Motility Disorder Drug Market?

The key growth driver is the rising prevalence of gastrointestinal disorders and increasing awareness about gut health.

3) Which is the largest region during the forecast period in the Global Gastric Motility Disorder Drug Market?

North America holds the largest market share, while Asia-Pacific is projected to grow at the fastest pace.

4) Which segment accounted for the largest market share in the Global Gastric Motility Disorder Drug Market?

The Prokinetic Agents segment held the largest market share in 2023.

5) Who are the key market players in the Global Gastric Motility Disorder Drug Market?

Key players include Takeda, Pfizer, AbbVie, Ipsen, Salix Pharmaceuticals, and Johnson & Johnson.